Moderna’s Covid-19 vaccine may offer longer-lasting protection than Pfizer’s, new research suggests, as governments and scientists debate who needs booster shots and when.
Recent studies show the Moderna jab prompts a stronger immune response than the rival mRNA vaccine from BioNTech/Pfizer, and that its effects wane more slowly.
Paul Burton, Moderna’s chief medical officer, said a stream of “extremely reassuring” studies in the past few weeks showed Moderna’s shot had “long-lived” efficacy, stood up to the Delta variant and could even help people with compromised immune systems.
您已閱讀7%（587字），剩余93%（7969字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。